Viridian Therapeutics, Inc.\DE (VRDN) stock
VRDNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30255% above fair value
$30.12+0.06 (+0.20%)
Close on Nov 18, 2026Market cap $3.41BP/E –Yield –
Viridian Therapeutics, Inc.\DE EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
No ev/ebitda figures for Viridian Therapeutics, Inc.\DE
Viridian Therapeutics, Inc.\DE has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?